Syngene International is all set to make an additional investment of upto $56 million in equity share capital of Syngene USA Inc (SUSA), a wholly owned subsidiary of the Company, in one or more tranches. The investment will be utilised to finance the cost of acquisition of biologics facility from Emergent Manufacturing Operations Baltimore, LLC., and for meeting the general corporate, and day-to-day operating requirements.
The investment is expected to be completed on or before March 31, 2026 or such other date mutually agreed between the parties. There will be no change in shareholding of the Company in SUSA. SUSA will continue to remain a wholly owned subsidiary of the Company.
Syngene International is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide.
